drugset / Trial / NCT04570423
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Timeline
- Start
- 2021-05-20
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflapegrastim | Protein / enzyme biologic | — | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Ifosfamide | Small molecule | — | — |
| Background | Vincristine | Small molecule | — | — |